Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 180Lymphoma 134Sarcoma 80Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Hodgkin Disease 50Lymphoma, Non-Hodgkin 49Leukemia 41Burkitt Lymphoma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 34Neuroblastoma 30Ovarian Neoplasms 26Multiple Myeloma 26Neoplasms 24Lymphoma, Large-Cell, Anaplastic 23Carcinoma, Hepatocellular 23Neoplasm Metastasis 20Lymphoma, Large-Cell, Immunoblastic 19Triple Negative Breast Neoplasms 18HIV Infections 18Urinary Bladder Neoplasms 15Acquired Immunodeficiency Syndrome 15Osteosarcoma 14Liposarcoma 14Leiomyosarcoma 13Histiocytoma, Malignant Fibrous 13Breast Neoplasms, Male 13Lymphoma, B-Cell, Marginal Zone 12Inflammatory Breast Neoplasms 12

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × Doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡